Additionally, the 36-month beta value for CASI is 0.61. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CASI is 3.83M and currently, short sellers hold a 1.97% ratio of that float. The average trading volume of CASI on November 26, 2024 was 27.67K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CASI) stock’s latest price update
CASI Pharmaceuticals Inc (NASDAQ: CASI)’s stock price has gone decline by -15.88 in comparison to its previous close of 5.10, however, the company has experienced a -23.67% decrease in its stock price over the last five trading days. accesswire.com reported 2024-11-15 that BEIJING, CHINA / ACCESSWIRE / November 15, 2024 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI) (“CASI” or the “Company”), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended September 30, 2024. Dr. Wei-Wu He, Chairman and CEO of CASI, said “The third quarter of 2024 marks a period of substantial progress for CASI as we continue to refine our company’s strategic focus on the development for organ transplant rejection and autoimmune diseases.
CASI’s Market Performance
CASI Pharmaceuticals Inc (CASI) has experienced a -23.67% fall in stock performance for the past week, with a -34.00% drop in the past month, and a -34.10% drop in the past quarter. The volatility ratio for the week is 11.51%, and the volatility levels for the past 30 days are at 9.31% for CASI. The simple moving average for the past 20 days is -23.45% for CASI’s stock, with a -13.29% simple moving average for the past 200 days.
Analysts’ Opinion of CASI
Many brokerage firms have already submitted their reports for CASI stocks, with BTIG Research repeating the rating for CASI by listing it as a “Buy.” The predicted price for CASI in the upcoming period, according to BTIG Research is $4 based on the research report published on May 18, 2021 of the previous year 2021.
Mizuho, on the other hand, stated in their research note that they expect to see CASI reach a price target of $3.80. The rating they have provided for CASI stocks is “Buy” according to the report published on April 26th, 2021.
Oppenheimer gave a rating of “Outperform” to CASI, setting the target price at $5 in the report published on October 23rd of the previous year.
CASI Trading at -25.37% from the 50-Day Moving Average
After a stumble in the market that brought CASI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.41% of loss for the given period.
Volatility was left at 9.31%, however, over the last 30 days, the volatility rate increased by 11.51%, as shares sank -26.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.74% lower at present.
During the last 5 trading sessions, CASI fell by -23.67%, which changed the moving average for the period of 200-days by -31.25% in comparison to the 20-day moving average, which settled at $5.60. In addition, CASI Pharmaceuticals Inc saw -40.08% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CASI
Current profitability levels for the company are sitting at:
- -1.72 for the present operating margin
- 0.55 for the gross margin
The net margin for CASI Pharmaceuticals Inc stands at -1.43. The total capital return value is set at -0.75. Equity return is now at value -136.05, with -43.41 for asset returns.
The debt to equity ratio resting at 1.38. The interest coverage ratio of the stock is -666.69.
Currently, EBITDA for the company is -21.54 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 2.82. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.33. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.20.
Conclusion
In conclusion, CASI Pharmaceuticals Inc (CASI) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
